Candel Therapeutics (NASDAQ:CADL) Releases Quarterly Earnings Results, Misses Estimates By $0.25 EPS

Candel Therapeutics (NASDAQ:CADL) issued its quarterly earnings data on Thursday. The company reported ($0.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.25), FiscalAI reports.

Candel Therapeutics Stock Down 1.0%

CADL stock traded down $0.12 during midday trading on Friday, reaching $11.68. 636,736 shares of the company were exchanged, compared to its average volume of 1,522,980. The company has a debt-to-equity ratio of 0.34, a quick ratio of 28.05 and a current ratio of 28.05. Candel Therapeutics has a 1-year low of $4.35 and a 1-year high of $11.90. The stock’s 50-day simple moving average is $9.62 and its 200 day simple moving average is $7.37. The company has a market cap of $855.87 million, a price-to-earnings ratio of -11.94 and a beta of -0.51.

Insider Buying and Selling at Candel Therapeutics

In related news, insider Francesca Barone sold 23,447 shares of the stock in a transaction on Monday, June 29th. The shares were sold at an average price of $10.06, for a total value of $235,876.82. Following the transaction, the insider directly owned 77,362 shares of the company’s stock, valued at $778,261.72. This trade represents a 23.26% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CTO Seshu Tyagarajan sold 7,000 shares of the firm’s stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $10.02, for a total value of $70,140.00. Following the transaction, the chief technology officer directly owned 83,865 shares in the company, valued at approximately $840,327.30. The trade was a 7.70% decrease in their position. The SEC filing for this sale provides additional information. Corporate insiders own 14.30% of the company’s stock.

Institutional Investors Weigh In On Candel Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CADL. BNP Paribas Financial Markets boosted its holdings in shares of Candel Therapeutics by 128.2% in the third quarter. BNP Paribas Financial Markets now owns 7,901 shares of the company’s stock valued at $40,000 after acquiring an additional 4,439 shares during the period. Tower Research Capital LLC TRC grew its position in shares of Candel Therapeutics by 361.7% during the second quarter. Tower Research Capital LLC TRC now owns 9,608 shares of the company’s stock worth $49,000 after acquiring an additional 7,527 shares during the last quarter. Invesco Ltd. acquired a new position in shares of Candel Therapeutics in the 1st quarter valued at $59,000. The Manufacturers Life Insurance Company acquired a new position in shares of Candel Therapeutics in the 2nd quarter valued at $70,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Candel Therapeutics by 37.7% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 16,748 shares of the company’s stock valued at $95,000 after purchasing an additional 4,583 shares during the last quarter. Hedge funds and other institutional investors own 13.93% of the company’s stock.

Analysts Set New Price Targets

CADL has been the topic of a number of recent research reports. Zacks Research upgraded shares of Candel Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Friday, May 15th. Stifel Nicolaus assumed coverage on shares of Candel Therapeutics in a report on Monday, July 13th. They set a “buy” rating and a $22.00 target price on the stock. Wall Street Zen raised shares of Candel Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 8th. HC Wainwright reaffirmed a “buy” rating and set a $23.00 price objective on shares of Candel Therapeutics in a research report on Thursday. Finally, Cantor Fitzgerald assumed coverage on Candel Therapeutics in a report on Monday, April 20th. They issued an “overweight” rating for the company. Seven analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $18.57.

Key Stories Impacting Candel Therapeutics

Here are the key news stories impacting Candel Therapeutics this week:

• Positive Sentiment: Analyst remains bullish: HC Wainwright reaffirmed its “Buy” rating and maintained a $23 price target, substantially above CADL’s recent trading level. The firm also projects a shift to positive earnings in future years. HC Wainwright reaffirms Buy rating and $23 price target
• Positive Sentiment: Pipeline progress supports the long-term story: Candel is targeting a BLA submission in the fourth quarter and expects its prostate-cancer therapy could become its first commercial product in 2027. Management described execution toward the filing as meaningful, helping sustain investor interest in the program’s commercial potential. CADL targets first commercial product in 2027
• Neutral Sentiment: Upcoming regulatory milestone: Candel is nearing a year-end BLA filing for its prostate-cancer drug, which analysts and investors view as a potential catalyst. However, the filing and any subsequent approval remain prospective, so execution and regulatory risk remain important. Candel nears year-end BLA filing
• Negative Sentiment: Quarterly loss exceeded expectations: Candel reported a second-quarter 2026 loss of $0.52 per share, compared with the consensus loss estimate of $0.27. The larger-than-expected loss highlights continued cash-burn concerns for the clinical-stage biotechnology company. Candel reports second-quarter 2026 results
• Negative Sentiment: Long-term earnings estimates were reduced: HC Wainwright lowered its FY2028 EPS forecast to $0.69 from $0.71 and its FY2029 forecast to $1.41 from $1.45. Although the firm remains bullish, the revisions modestly temper expectations for future profitability.

Candel Therapeutics Company Profile

Candel Therapeutics (NASDAQ:CADL) is a clinical-stage immuno-oncology company focused on the development of next-generation oncolytic viral therapies designed to treat solid tumors. The company’s lead candidate, CAN-2409, is a locally administered, gene-delivered viral therapy engineered to selectively replicate in cancer cells and induce immunogenic cell death. Candel leverages proprietary virus engineering platforms to enhance tumor-specific replication and stimulate anti-tumor immune responses, aiming to improve outcomes for patients with high unmet medical needs.

In addition to its lead program, Candel’s pipeline includes CAN-3110, an oncolytic herpes simplex virus targeting recurrent high-grade glioma, and other novel viral constructs being explored for a variety of solid tumor indications.